Q-linea AB (QLINEA) Price & Analysis

Compare

3 Followers

QLINEA Stock Chart & Stats

kr29.00

>-kr0.01(-3.85%)

At close: Mar 06 4:00 PM EST

kr29.00

>-kr0.01(-3.85%)

Day’s Range― - ―

52-Week Rangekr20.79 - kr383.32

Previous CloseN/A

Volume6.05M

Average Volume (3M)13.43K

Market Cap

kr449.22M

Enterprise Value-kr89.72M

Total Cash (Recent Filing)kr258.11M

Total Debt (Recent Filing)kr7.71M

Price to Earnings (P/E)―

Beta3.24

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.73

Shares Outstanding18,949,081

10 Day Avg. Volume10,725

30 Day Avg. Volume13,430

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.49

Price to Sales (P/S)14.97

P/FCF Ratio-0.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Revenue ModelQ-linea's business depends on instrument placements plus repeat consumable and service sales. That model creates a durable, annuity-like revenue stream as installed base and test volumes scale, supporting predictable long-term revenue and margin improvement if utilization grows.

Low Current LeverageModest debt and low leverage reduce near-term refinancing and interest risks, giving management flexibility to fund commercialization and R&D. With a low debt burden the company can prioritize building installed base without immediate pressure from creditors, aiding execution over months.

2025 Top-line ReboundA strong revenue rebound signals improving commercial traction and potential product-market fit in hospitals. Sustained top-line recovery supports scale benefits for consumables, increases the addressable recurring revenue pool, and can help absorb fixed costs as adoption expands.

Bears Say

Negative Gross ProfitPersistently negative gross profit implies product costs or pricing are not covering direct costs, undermining the sustainability of recurring consumable economics. Without margin recovery, scaling revenue will not translate into positive operating cash flow or durable profitability over the medium term.

Severe Cash BurnConsistent, large negative operating and free cash flows deplete liquidity and increase the likelihood of future fundraising or dilution. Heavy cash burn constrains investment in sales, support and product development, raising execution risk and pressuring the balance sheet within months.

Uneven Commercialization / Revenue VolatilitySharp swings in revenue reflect inconsistent market adoption and commercial execution. Volatility limits predictability of installed base growth and consumable lift, complicating operational planning and making multi-quarter scaling of recurring revenues and margin improvement uncertain.

Q-linea AB News

Q-linea Boosts Capital and Global Footprint as ASTar Rollout Accelerates

Q-linea AB ( ($SE:QLINEA) ) has issued an update. Q-linea reported full-year 2025 net sales of SEK 11.1...

13d ago

Q-linea Wins ASTar Contract with Major U.S. Hospital System

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has signed a contract for the adoption...

29d ago

Q-linea Reshapes US Commercial Leadership to Drive ASTar® Adoption

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has announced a reshaping of its...

1M ago

Q-linea Enters South Asian Market With First Distribution Deal in Bangladesh

Q-linea AB ( ($SE:QLINEA) ) has shared an announcement. Q-linea has signed its first distribution agreement in South...

2M ago

Q-linea’s ASTar Chosen to Replace Accelerate Pheno in Italian Laboratories

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has been selected to supply its...

2M ago

Q-linea Secures First U.S. Hospital Deployments of ASTar Rapid Testing System

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has achieved its first clinical implementations of...

2M ago

Q-linea AB Expands Share Capital to Strengthen Market Position

The latest announcement is out from Q-linea AB ( ($SE:QLINEA) ). Q-linea AB has increased its total number...

3M ago

Q-linea Announces Organizational Restructuring and Leadership Changes

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea AB has announced a reorganization and...

3M ago

Q-linea Submits FDA Application for Expanded ASTar BC G- Panel Claims

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has submitted a 510(k) application to the...

3M ago

Q-linea Completes Directed Share Issue to Wellsford Limited

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB, a company listed on Nasdaq Stockholm, has...

3M ago

QLINEA FAQ

What was Q-linea AB’s price range in the past 12 months?

Q-linea AB lowest stock price was kr20.79 and its highest was kr383.32 in the past 12 months.

What is Q-linea AB’s market cap?

Q-linea AB’s market cap is kr449.22M.

When is Q-linea AB’s upcoming earnings report date?

Q-linea AB’s upcoming earnings report date is Apr 30, 2026 which is in 72 days.

How were Q-linea AB’s earnings last quarter?

Q-linea AB released its earnings results on Feb 04, 2026. The company reported -kr3.733 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.733.

Is Q-linea AB overvalued?

According to Wall Street analysts Q-linea AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Q-linea AB pay dividends?

Q-linea AB does not currently pay dividends.

What is Q-linea AB’s EPS estimate?

Q-linea AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Q-linea AB have?

Q-linea AB has 18,949,081 shares outstanding.

What happened to Q-linea AB’s price movement after its last earnings report?

Q-linea AB reported an EPS of -kr3.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.68%.

Which hedge fund is a major shareholder of Q-linea AB?

Currently, no hedge funds are holding shares in SE:QLINEA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Q-linea AB

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.